Objective To observe and analyze the therapeutic effect of pirfenidone on pulmonary interstitial fibrosis secondary to COVID-19.Methods Clinical data of 2 patients with pulmonary interstitial fibrosis after severe COVID-19 were collected and followed up after discharged from our hospital,and the therapeutic effect of pirfenidone on anti-fibrosis secondary to COVID-19 was analyzed.Results After the two patients were treated with pirfenidone for 15 weeks and 9 weeks respectively,dynamic review of chest CT showed that the degree of pulmonary fibrosis in both patients was significantly reduced.Conclusions Pirfenidone may be effective in improving pulmonary fibrosis after COVID-19,but it still needs to be confirmed by longer duration of follow-up and clinical studies with more samples.
维普
万方数据